Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
CANCER:
Endocrine Cancer
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Associations
(406)
News
Trials
VERI cancer hierarchy
Reset Filters
No biomarker
Thyroid Gland Medullary Carcinoma
No biomarker
Thyroid Gland Medullary Carcinoma
cabozantinib capsule
Sensitive: A1 - Approval
cabozantinib capsule
Sensitive
:
A1
cabozantinib capsule
Sensitive: A1 - Approval
cabozantinib capsule
Sensitive
:
A1
RET fusion
Thyroid Gland Carcinoma
RET fusion
Thyroid Gland Carcinoma
pralsetinib
Sensitive: A1 - Approval
pralsetinib
Sensitive
:
A1
pralsetinib
Sensitive: A1 - Approval
pralsetinib
Sensitive
:
A1
No biomarker
Thyroid Gland Carcinoma
No biomarker
Thyroid Gland Carcinoma
cabozantinib tablet
Sensitive: A1 - Approval
cabozantinib tablet
Sensitive
:
A1
cabozantinib tablet
Sensitive: A1 - Approval
cabozantinib tablet
Sensitive
:
A1
RET mutation
Thyroid Gland Medullary Carcinoma
RET mutation
Thyroid Gland Medullary Carcinoma
selpercatinib
Sensitive: A1 - Approval
selpercatinib
Sensitive
:
A1
selpercatinib
Sensitive: A1 - Approval
selpercatinib
Sensitive
:
A1
No biomarker
Adrenal Cortex Carcinoma
No biomarker
Adrenal Cortex Carcinoma
mitotane
Sensitive: A1 - Approval
mitotane
Sensitive
:
A1
mitotane
Sensitive: A1 - Approval
mitotane
Sensitive
:
A1
RET fusion
Thyroid Gland Carcinoma
RET fusion
Thyroid Gland Carcinoma
selpercatinib
Sensitive: A1 - Approval
selpercatinib
Sensitive
:
A1
selpercatinib
Sensitive: A1 - Approval
selpercatinib
Sensitive
:
A1
No biomarker
Thyroid Gland Hurthle Cell Carcinoma
No biomarker
Thyroid Gland Hurthle Cell Carcinoma
sorafenib
Sensitive: A1 - Approval
sorafenib
Sensitive
:
A1
sorafenib
Sensitive: A1 - Approval
sorafenib
Sensitive
:
A1
No biomarker
Thyroid Gland Follicular Carcinoma
No biomarker
Thyroid Gland Follicular Carcinoma
sorafenib
Sensitive: A1 - Approval
sorafenib
Sensitive
:
A1
sorafenib
Sensitive: A1 - Approval
sorafenib
Sensitive
:
A1
No biomarker
Thyroid Gland Papillary Carcinoma
No biomarker
Thyroid Gland Papillary Carcinoma
sorafenib
Sensitive: A1 - Approval
sorafenib
Sensitive
:
A1
sorafenib
Sensitive: A1 - Approval
sorafenib
Sensitive
:
A1
No biomarker
Thyroid Gland Follicular Carcinoma
No biomarker
Thyroid Gland Follicular Carcinoma
lenvatinib
Sensitive: A1 - Approval
lenvatinib
Sensitive
:
A1
lenvatinib
Sensitive: A1 - Approval
lenvatinib
Sensitive
:
A1
No biomarker
Thyroid Gland Hurthle Cell Carcinoma
No biomarker
Thyroid Gland Hurthle Cell Carcinoma
lenvatinib
Sensitive: A1 - Approval
lenvatinib
Sensitive
:
A1
lenvatinib
Sensitive: A1 - Approval
lenvatinib
Sensitive
:
A1
No biomarker
Thyroid Gland Papillary Carcinoma
No biomarker
Thyroid Gland Papillary Carcinoma
lenvatinib
Sensitive: A1 - Approval
lenvatinib
Sensitive
:
A1
lenvatinib
Sensitive: A1 - Approval
lenvatinib
Sensitive
:
A1
No biomarker
Thyroid Gland Medullary Carcinoma
No biomarker
Thyroid Gland Medullary Carcinoma
vandetanib
Sensitive: A1 - Approval
vandetanib
Sensitive
:
A1
vandetanib
Sensitive: A1 - Approval
vandetanib
Sensitive
:
A1
BRAF V600E
Thyroid Gland Anaplastic Carcinoma
BRAF V600E
Thyroid Gland Anaplastic Carcinoma
trametinib + dabrafenib
Sensitive: A1 - Approval
trametinib + dabrafenib
Sensitive
:
A1
trametinib + dabrafenib
Sensitive: A1 - Approval
trametinib + dabrafenib
Sensitive
:
A1
RET mutation
Thyroid Gland Medullary Carcinoma
RET mutation
Thyroid Gland Medullary Carcinoma
pralsetinib
Sensitive: A1 - Approval
pralsetinib
Sensitive
:
A1
pralsetinib
Sensitive: A1 - Approval
pralsetinib
Sensitive
:
A1
BRAF V600E
Thyroid Gland Anaplastic Carcinoma
BRAF V600E
Thyroid Gland Anaplastic Carcinoma
dabrafenib
Sensitive: A1 - Approval
dabrafenib
Sensitive
:
A1
dabrafenib
Sensitive: A1 - Approval
dabrafenib
Sensitive
:
A1
No biomarker
Thyroid Gland Carcinoma
No biomarker
Thyroid Gland Carcinoma
lenvatinib
Sensitive: A1 - Approval
lenvatinib
Sensitive
:
A1
lenvatinib
Sensitive: A1 - Approval
lenvatinib
Sensitive
:
A1
NTRK1 fusion
Thyroid Gland Follicular Carcinoma
NTRK1 fusion
Thyroid Gland Follicular Carcinoma
entrectinib
Sensitive: A2 - Guideline
entrectinib
Sensitive
:
A2
entrectinib
Sensitive: A2 - Guideline
entrectinib
Sensitive
:
A2
No biomarker
Thyroid Gland Medullary Carcinoma
No biomarker
Thyroid Gland Medullary Carcinoma
dacarbazine
Sensitive: A2 - Guideline
dacarbazine
Sensitive
:
A2
dacarbazine
Sensitive: A2 - Guideline
dacarbazine
Sensitive
:
A2
NTRK2 fusion
Thyroid Gland Follicular Carcinoma
NTRK2 fusion
Thyroid Gland Follicular Carcinoma
entrectinib
Sensitive: A2 - Guideline
entrectinib
Sensitive
:
A2
entrectinib
Sensitive: A2 - Guideline
entrectinib
Sensitive
:
A2
NTRK3 fusion
Thyroid Gland Follicular Carcinoma
NTRK3 fusion
Thyroid Gland Follicular Carcinoma
entrectinib
Sensitive: A2 - Guideline
entrectinib
Sensitive
:
A2
entrectinib
Sensitive: A2 - Guideline
entrectinib
Sensitive
:
A2
NTRK1 fusion
Thyroid Gland Hurthle Cell Carcinoma
NTRK1 fusion
Thyroid Gland Hurthle Cell Carcinoma
entrectinib
Sensitive: A2 - Guideline
entrectinib
Sensitive
:
A2
entrectinib
Sensitive: A2 - Guideline
entrectinib
Sensitive
:
A2
NTRK2 fusion
Thyroid Gland Hurthle Cell Carcinoma
NTRK2 fusion
Thyroid Gland Hurthle Cell Carcinoma
entrectinib
Sensitive: A2 - Guideline
entrectinib
Sensitive
:
A2
entrectinib
Sensitive: A2 - Guideline
entrectinib
Sensitive
:
A2
NTRK1 fusion
Thyroid Gland Follicular Carcinoma
NTRK1 fusion
Thyroid Gland Follicular Carcinoma
larotrectinib
Sensitive: A2 - Guideline
larotrectinib
Sensitive
:
A2
larotrectinib
Sensitive: A2 - Guideline
larotrectinib
Sensitive
:
A2
NTRK2 fusion
Thyroid Gland Follicular Carcinoma
NTRK2 fusion
Thyroid Gland Follicular Carcinoma
larotrectinib
Sensitive: A2 - Guideline
larotrectinib
Sensitive
:
A2
larotrectinib
Sensitive: A2 - Guideline
larotrectinib
Sensitive
:
A2
NTRK3 fusion
Thyroid Gland Follicular Carcinoma
NTRK3 fusion
Thyroid Gland Follicular Carcinoma
larotrectinib
Sensitive: A2 - Guideline
larotrectinib
Sensitive
:
A2
larotrectinib
Sensitive: A2 - Guideline
larotrectinib
Sensitive
:
A2
No biomarker
Thyroid Gland Anaplastic Carcinoma
No biomarker
Thyroid Gland Anaplastic Carcinoma
Sensitive: A2 - Guideline
Sensitive
:
A2
Sensitive: A2 - Guideline
Sensitive
:
A2
No biomarker
Adrenal Cortex Carcinoma
No biomarker
Adrenal Cortex Carcinoma
pembrolizumab
Sensitive: A2 - Guideline
pembrolizumab
Sensitive
:
A2
pembrolizumab
Sensitive: A2 - Guideline
pembrolizumab
Sensitive
:
A2
No biomarker
Adrenal Cortex Carcinoma
No biomarker
Adrenal Cortex Carcinoma
cisplatin
Sensitive: A2 - Guideline
cisplatin
Sensitive
:
A2
cisplatin
Sensitive: A2 - Guideline
cisplatin
Sensitive
:
A2
NTRK2 fusion
Thyroid Gland Papillary Carcinoma
NTRK2 fusion
Thyroid Gland Papillary Carcinoma
larotrectinib
Sensitive: A2 - Guideline
larotrectinib
Sensitive
:
A2
larotrectinib
Sensitive: A2 - Guideline
larotrectinib
Sensitive
:
A2
TMB-H
Thyroid Gland Hurthle Cell Carcinoma
TMB-H
Thyroid Gland Hurthle Cell Carcinoma
pembrolizumab
Sensitive: A2 - Guideline
pembrolizumab
Sensitive
:
A2
pembrolizumab
Sensitive: A2 - Guideline
pembrolizumab
Sensitive
:
A2
No biomarker
Thyroid Gland Hurthle Cell Carcinoma
No biomarker
Thyroid Gland Hurthle Cell Carcinoma
denosumab
Sensitive: A2 - Guideline
denosumab
Sensitive
:
A2
denosumab
Sensitive: A2 - Guideline
denosumab
Sensitive
:
A2
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login